Recently stock market analysts have updated their consensus ratings on shares of Brainstorm Cell Therapeutics (BCLI).

Most recent broker ratings

12/28/2015 – Brainstorm Cell Therapeutics had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 5 price target on the stock.

08/13/2014 – Brainstorm Cell Therapeutics had its “outperform” rating reiterated by analysts at Zacks. They now have a USD 0.5 price target on the stock.

Brainstorm Cell Therapeutics has a 50 day moving average of 2.45 and a 200 day moving average of 2.55. The stock’s market capitalization is 40.14M, it has a 52-week low of 1.90 and a 52-week high of 4.02.

The share price of the company (BCLI) was down -1.81%, with a high of 2.21 during the day and the volume of Brainstorm Cell Therapeutics shares traded was 50033.

View other investors thoughts on Brainstorm Cell Therapeutics with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.